Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. brain activity
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Brain Activity Articles & Analysis: Older

46 news found

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

According to their announcement: Adults can be exposed to lead dust or lead fumes during renovation or remodeling activities in older homes with lead-based paints. They can also be exposed through certain jobs and hobbies. ...

ByCochrane & Associates, LLC


Dreams and Sleep Quality:  Finding the Best Anti-Snoring Device

Dreams and Sleep Quality: Finding the Best Anti-Snoring Device

Are you restless during sleep at night? Do you often wake up at night due to bad dreams or have difficulty in falling asleep? Are you anxious before you sleep? There are a variety of issues that can hamper proper and restful sleep at night, apart from snoring. According to University of Arizona clinical professor of medicine and dream specialist, Rubin Naiman, PhD, the two key components of good ...

ByTannerMedico A/S - Asonor


CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...

ByAriana Pharma


Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...

BySage Therapeutics


BESA Connectivity 2.0 preview

BESA Connectivity 2.0 preview

BESA Connectivity 2.0 is just around the corner! As a successor to the best-in-class tool for functional brain connectivity analysis, it comes with a bunch of great new features and improvements. Here are some of the most important news about this software*: Batch processing for both time-frequency and connectivity workflows – analyze your complete subject set in one go, also for ...

ByBESA GmbH


#EEGinEveryday - mbt meets BESA: An interview with our expert Mateusz Rusiniak

#EEGinEveryday - mbt meets BESA: An interview with our expert Mateusz Rusiniak

We have investigated these interesting activities using BESA software together with mBrainTrain, a manufacturer and pioneer of fully portable, mobile EEG devices, and have come to interesting results. ...

ByBESA GmbH


Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression. The 11 new analyses are being presented at the 2022 Psych Congress in New Orleans, ...

BySage Therapeutics


Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors

Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors including high-grade glioma. The Phase I/II trial is an ...

ByJubilant Therapeutics Inc.


Newly Published Studies Show Motor Recovery in Chronic Stroke Patients

Newly Published Studies Show Motor Recovery in Chronic Stroke Patients

Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...

ByNeurolutions


VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders

VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...

ByVeriSIM Life


Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem Expands R&D Program to Include Multiple Sclerosis

(TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). ...

ByKadimastem Ltd.


Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US ...

BySynchron, Inc.


Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action Conference

Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action Conference

Mazmanian, Ph.D., Luis B. and Nelly Soux Professor of Microbiology and Heritage Medical Research Institute Investigator at Caltech, is a leader in the field of microbiology, the interaction between the gut microbiome and the brain, and the impact of this gut-brain axis on neurological disorders and conditions. His groundbreaking work established several key ...

ByAxial Therapeutics Inc.


Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...

ByInscopix Inc.


Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics

Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, ...

ByInscopix Inc.


NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

First Quarter and Recent Business Updates Submitted clearance request to FDA for less than 30-day use of NeuroOne's Evo® sEEG Electrode, which has already been 510(k) cleared for temporary (less than 24 hours) use Exhibited our Evo cortical electrode product family at the American Epilepsy Society Meeting in Zimmer Biomet's booth Presented poster with the following title at American ...

ByNeuroOne Medical Technologies Corporation


New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior

New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior

The studies in mice showed that gut-derived metabolites can enter the brain and disrupt the maturation of oligodendrocytes, which leads to alteration of myelination and region-specific changes in brain activity and functional connectivity. The paper, “A gut-derived metabolite alters brain activity and ...

ByAxial Therapeutics Inc.


CD BioGlyco Provides a Comprehensive List of Custom Carbohydrate Synthesis Services

CD BioGlyco Provides a Comprehensive List of Custom Carbohydrate Synthesis Services

Carbohydrates are the main components and energy supplies of living cell structures and have important functions in regulating cellular activities. There are three main forms of carbohydrates in the body, glucose, glycogen and sugary complexes, and the physiological function of carbohydrates is related to the types of carbohydrates ingested by foods and the forms present in the ...

ByCD BioGlyco.


Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately. Dr. Linda M. Liau is Professor and W. Eugene Stern Chair of the Department of Neurosurgery at the ...

ByClearPoint Neuro, Inc.


BrainScope Completes Agreement with 18,000 Member Yankee Alliance

BrainScope Completes Agreement with 18,000 Member Yankee Alliance

BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild traumatic brain injuries (mTBIs), including brain bleed and concussion. When used by Emergency Departments (ED) in triage, BrainScope has demonstrated the potential to reduce the use of head CAT Scans by more than 30% while also ...

ByBrainScope Company, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT